Drug Combination Details
| General Information of the Combination (ID: C61221) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Everolimus Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
|
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | EIF4EBP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | ||
| LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
| In-vivo Model | The mice were inoculated with 100 ml (50% Matrigel/PBS) SKOV3 cell suspension (3*106) to both dorsal flanks of the mice . | |||||
| Experimental
Result(s) |
Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | ||
| LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
| In-vivo Model | Six-week-old SCID (severe combined immuno deficiency) mice were inoculated with 100 ul (50% Matrigel/PBS) LNCaP cells suspension (6 * 106) to either dorsal flank with 25-gauge syringe. | |||||
| Experimental
Result(s) |
Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells. | |||||
